vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and ResMed (RMD). Click either name above to swap in a different company.
Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.4B, roughly 1.2× ResMed). ResMed runs the higher net margin — 27.6% vs 23.1%, a 4.5% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 11.0%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs 7.9%).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.
EW vs RMD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $1.4B |
| Net Profit | $380.7M | $392.6M |
| Gross Margin | 78.0% | 61.8% |
| Operating Margin | 1.8% | 34.6% |
| Net Margin | 23.1% | 27.6% |
| Revenue YoY | 16.7% | 11.0% |
| Net Profit YoY | 6.8% | 13.9% |
| EPS (diluted) | $0.66 | $2.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $1.4B | ||
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.2B |
| Q2 26 | — | $392.6M | ||
| Q1 26 | $380.7M | — | ||
| Q4 25 | $91.2M | $392.6M | ||
| Q3 25 | $291.1M | $348.5M | ||
| Q2 25 | $333.2M | $379.7M | ||
| Q1 25 | $358.0M | $365.0M | ||
| Q4 24 | $385.6M | $344.6M | ||
| Q3 24 | $3.1B | $311.4M |
| Q2 26 | — | 61.8% | ||
| Q1 26 | 78.0% | — | ||
| Q4 25 | 78.1% | 61.8% | ||
| Q3 25 | 77.8% | 61.5% | ||
| Q2 25 | 77.5% | 60.8% | ||
| Q1 25 | 78.7% | 59.3% | ||
| Q4 24 | 78.9% | 58.6% | ||
| Q3 24 | 80.6% | 58.6% |
| Q2 26 | — | 34.6% | ||
| Q1 26 | 1.8% | — | ||
| Q4 25 | 9.6% | 34.6% | ||
| Q3 25 | 19.8% | 33.4% | ||
| Q2 25 | 26.8% | 33.7% | ||
| Q1 25 | 27.9% | 33.0% | ||
| Q4 24 | 22.6% | 32.5% | ||
| Q3 24 | 25.9% | 31.6% |
| Q2 26 | — | 27.6% | ||
| Q1 26 | 23.1% | — | ||
| Q4 25 | 5.8% | 27.6% | ||
| Q3 25 | 18.7% | 26.1% | ||
| Q2 25 | 21.7% | 28.2% | ||
| Q1 25 | 25.3% | 28.3% | ||
| Q4 24 | 27.8% | 26.9% | ||
| Q3 24 | 226.7% | 25.4% |
| Q2 26 | — | $2.68 | ||
| Q1 26 | $0.66 | — | ||
| Q4 25 | $0.16 | $2.68 | ||
| Q3 25 | $0.50 | $2.37 | ||
| Q2 25 | $0.56 | $2.58 | ||
| Q1 25 | $0.61 | $2.48 | ||
| Q4 24 | $0.65 | $2.34 | ||
| Q3 24 | $5.13 | $2.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.4B |
| Total DebtLower is stronger | — | $663.8M |
| Stockholders' EquityBook value | — | $6.3B |
| Total Assets | — | $8.5B |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $1.4B | ||
| Q1 26 | — | — | ||
| Q4 25 | $4.2B | $1.4B | ||
| Q3 25 | $3.8B | $1.4B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $3.9B | $932.7M | ||
| Q4 24 | $4.0B | $521.9M | ||
| Q3 24 | $4.4B | $426.4M |
| Q2 26 | — | $663.8M | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M |
| Q2 26 | — | $6.3B | ||
| Q1 26 | — | — | ||
| Q4 25 | $10.3B | $6.3B | ||
| Q3 25 | $10.2B | $6.1B | ||
| Q2 25 | $10.5B | $6.0B | ||
| Q1 25 | $10.1B | $5.5B | ||
| Q4 24 | $10.0B | $5.3B | ||
| Q3 24 | $9.5B | $5.2B |
| Q2 26 | — | $8.5B | ||
| Q1 26 | — | — | ||
| Q4 25 | $13.7B | $8.5B | ||
| Q3 25 | $13.3B | $8.3B | ||
| Q2 25 | $13.5B | $8.2B | ||
| Q1 25 | $13.0B | $7.6B | ||
| Q4 24 | $13.1B | $7.1B | ||
| Q3 24 | $13.0B | $7.2B |
| Q2 26 | — | 0.11× | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
